223 related articles for article (PubMed ID: 23851309)
1. Quantitative proteomic analysis of HER2 normal and overexpressing MCF-7 breast cancer cells revealed proteomic changes accompanied with HER2 gene amplification.
Tang Y; Mackey J; Lai R; Ghosh S; Santos C; Graham K; Damaraju S; Pasdar M; Li L
J Proteomics; 2013 Oct; 91():200-9. PubMed ID: 23851309
[TBL] [Abstract][Full Text] [Related]
2. Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin).
Oliveras-Ferraros C; Vazquez-Martin A; Martin-Castilló B; Pérez-Martínez MC; Cufí S; Del Barco S; Bernado L; Brunet J; López-Bonet E; Menendez JA
Int J Oncol; 2010 Sep; 37(3):669-78. PubMed ID: 20664936
[TBL] [Abstract][Full Text] [Related]
3. Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases.
Priedigkeit N; Hartmaier RJ; Chen Y; Vareslija D; Basudan A; Watters RJ; Thomas R; Leone JP; Lucas PC; Bhargava R; Hamilton RL; Chmielecki J; Puhalla SL; Davidson NE; Oesterreich S; Brufsky AM; Young L; Lee AV
JAMA Oncol; 2017 May; 3(5):666-671. PubMed ID: 27926948
[TBL] [Abstract][Full Text] [Related]
4. Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells.
Vazquez-Martin A; Oliveras-Ferraros C; Colomer R; Brunet J; Menendez JA
Ann Oncol; 2008 Jun; 19(6):1097-109. PubMed ID: 18283037
[TBL] [Abstract][Full Text] [Related]
5. Mass spectrometry (LC-MS/MS) identified proteomic biosignatures of breast cancer in proximal fluid.
Whelan SA; He J; Lu M; Souda P; Saxton RE; Faull KF; Whitelegge JP; Chang HR
J Proteome Res; 2012 Oct; 11(10):5034-45. PubMed ID: 22934887
[TBL] [Abstract][Full Text] [Related]
6. Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-α.
Ceran C; Cokol M; Cingoz S; Tasan I; Ozturk M; Yagci T
BMC Cancer; 2012 Oct; 12():450. PubMed ID: 23033967
[TBL] [Abstract][Full Text] [Related]
7. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
8. The positive is inside the negative: HER2-negative tumors can express the HER2 intracellular domain and present a HER2-positive phenotype.
Panis C; Pizzatti L; Corrêa S; Binato R; Lemos GF; da Silva do Amaral Herrera AC; Seixas TF; Cecchini R; Abdelhay E
Cancer Lett; 2015 Feb; 357(1):186-195. PubMed ID: 25434795
[TBL] [Abstract][Full Text] [Related]
9. Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer.
Zhang D; Tai LK; Wong LL; Chiu LL; Sethi SK; Koay ES
Mol Cell Proteomics; 2005 Nov; 4(11):1686-96. PubMed ID: 16048908
[TBL] [Abstract][Full Text] [Related]
10. Radiosensitizing effect of lapatinib in human epidermal growth factor receptor 2-positive breast cancer cells.
Yu T; Cho BJ; Choi EJ; Park JM; Kim DH; Kim IA
Oncotarget; 2016 Nov; 7(48):79089-79100. PubMed ID: 27738326
[TBL] [Abstract][Full Text] [Related]
11. Protein array technology to detect HER2 (erbB-2)-induced 'cytokine signature' in breast cancer.
Vazquez-Martin A; Colomer R; Menendez JA
Eur J Cancer; 2007 May; 43(7):1117-24. PubMed ID: 17379503
[TBL] [Abstract][Full Text] [Related]
12. Tissue Microarray Is a Reliable Tool for the Evaluation of HER2 Amplification in Breast Cancer.
Furrer D; Jacob S; Caron C; Sanschagrin F; Provencher L; Diorio C
Anticancer Res; 2016 Sep; 36(9):4661-6. PubMed ID: 27630309
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
14. Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).
Martin-Castillo B; Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Moreno JM; Corominas-Faja B; Urruticoechea A; Martín ÁG; López-Bonet E; Menendez JA
Cell Cycle; 2013 Jan; 12(2):225-45. PubMed ID: 23255137
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
16. Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer.
Díaz-Gil L; Brasó-Maristany F; Locatelli C; Centa A; Győrffy B; Ocaña A; Prat A; Pandiella A
J Exp Clin Cancer Res; 2021 Oct; 40(1):313. PubMed ID: 34620206
[TBL] [Abstract][Full Text] [Related]
17. FSIP1 binds HER2 directly to regulate breast cancer growth and invasiveness.
Liu T; Zhang H; Sun L; Zhao D; Liu P; Yan M; Zaidi N; Izadmehr S; Gupta A; Abu-Amer W; Luo M; Yang J; Ou X; Wang Y; Bai X; Wang Y; New MI; Zaidi M; Yuen T; Liu C
Proc Natl Acad Sci U S A; 2017 Jul; 114(29):7683-7688. PubMed ID: 28674022
[TBL] [Abstract][Full Text] [Related]
18. Proteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies Mage-A4 as potential therapeutic target in estrogen receptor negative breast cancer.
Cabezón T; Gromova I; Gromov P; Serizawa R; Timmermans Wielenga V; Kroman N; Celis JE; Moreira JM
Mol Cell Proteomics; 2013 Feb; 12(2):381-94. PubMed ID: 23172894
[TBL] [Abstract][Full Text] [Related]
19. miR-200c suppresses stemness and increases cellular sensitivity to trastuzumab in HER2+ breast cancer.
Tang H; Song C; Ye F; Gao G; Ou X; Zhang L; Xie X; Xie X
J Cell Mol Med; 2019 Dec; 23(12):8114-8127. PubMed ID: 31599500
[TBL] [Abstract][Full Text] [Related]
20. Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells.
Joshi JP; Brown NE; Griner SE; Nahta R
Biochem Pharmacol; 2011 Nov; 82(9):1090-9. PubMed ID: 21803025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
